VetSheet

伊那力農

Inamrinone

Inamrinone lactate

正性肌力藥物IV狗貓

別名: Inocor · Amcoral · Vesistol · Wincoram · Amrinone lactate · Win-40680

由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本

1-3 mg/kg IV as a slow IV bolus followed by a 10-100 micrograms/kg/min IV CRI; ½ the initial bolus may be administered 20-30 minutes after the first bolus.IV· CRI

這是依速率計算的持續輸注（CRI）劑量；須計算輸注速率，不能只依體重換算。

劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。

各物種劑量

🌎 NA — North America🌍 EU — Europe

狗

適應症劑量途徑頻次療程地區
Positive inotropic agent1-3 mg/kg IV as a slow IV bolus followed by a 10-100 micrograms/kg/min IV CRI; ½ the initial bolus may be administered 20-30 minutes after the first bolus.IVCRI—🌎 NA
Positive inotropic agent1-3 mg/kg IV followed by a 30-100 micrograms/kg/min IV CRIIVCRI—🌎 NA
Positive inotropic agent2 mg/kg bolus IV , followed by 30-300 micrograms/kg/min IV infusionIVCRI—🌎 NA
For patients coming off cardiopulmonary bypass with poor cardiac contractility0.25-0.6 mg/kg loading, then 5-45 micrograms/kg/min CRIIVCRI—🌎 NA
Adjunctive treatment for calcium channel blocker overdose30-100 micrograms/kg/min CRI.IVCRI—🌎 NA
  • Adjunctive treatment for calcium channel blocker overdose: Alternative to dopamine or dobutamine; used with fluids, IV calcium, and potentially glucagon.

貓

適應症劑量途徑頻次療程地區
Positive inotropic agent1-3 mg/kg IV followed by 30-100 micro-grams/kg/min IV infusionIVCRI—🌎 NA
Positive inotropic agent1-3 mg/kg IV as a slow IV bolus followed by a 10-100 micrograms/kg/min IV CRI; ½ the initial bolus may be administered 20-30 minutes after the first bolus.IVCRI—🌎 NA

劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。

正在看診？VetSheet 的 AI 會把藥物、劑量與療程直接寫入結構化的看診紀錄。了解 VetSheet 如何運作

概覽

伊那力農（Inamrinone，原名氨力農 Amrinone）是一種​雙吡啶類正性肌力藥物​與血管擴張劑。

  • 作為短期治療充血性心臟衰竭（CHF）的​二線藥物​。
  • 價格非常昂貴，且需要密集的醫療監測。

​臨床提示：​ 該藥物名稱從 amrinone 更改為 inamrinone，是為了避免與抗心律不整藥物胺碘酮（amiodarone）混淆而導致致命的給藥錯誤。

作用機轉

Inamrinone acts primarily as a phosphodiesterase III (PDE3) inhibitor.

  • Inhibition of PDE3 → decreased breakdown of intracellular cyclic AMP (cAMP) → increased intracellular calcium in the myocardium → positive inotropy (direct stimulation of cardiac contractility).
  • In vascular smooth muscle, increased cAMP leads to relaxation → vasodilation, which effectively reduces both cardiac preload and afterload.

安全性與警告

禁忌症

  • Severe aortic or pulmonic valve disease
  • Hypersensitivity to inamrinone or bisulfites

不良反應

  • Arrhythmias
  • Hypotension
  • Vomiting
  • Diarrhea
  • Thrombocytopenia (particularly with prolonged therapy)
  • Hepatotoxicity
  • Hypersensitivity reactions (variable symptomatology: pericarditis to myositis)

注意事項

Contraindicated in severe aortic or pulmonic valve disease. Use extreme caution in patients with hypertrophic cardiomyopathy. Reproductive safety data are conflicting (FDA Category C); use only when benefits outweigh risks. It is unknown if it is secreted in milk; exercise caution. Must only be used in settings where appropriate cardiovascular monitoring can be employed.

藥物交互作用

Digoxin

Additive inotropic effect; generally considered a positive drug interaction.

Disopyramide

May cause excessive hypotension when used concurrently.

監測

  • Blood pressure
  • Heart rate/rhythm (continuous ECG recommended)
  • Body weight
  • Platelet counts

藥物動力學

吸收

Rapidly absorbed after oral administration, though no oral commercial dosage forms are available. After initial IV injection, effects begin within 2-3 minutes and peak within 10 minutes.

分佈

Apparent volume of distribution is 1.2 L/kg (in humans). Exhibits low to moderate protein binding (10-49%). Unknown if it crosses the placenta, blood-brain barrier, or enters maternal milk.

代謝

Not extensively described in the monograph.

排除

Eliminated primarily via the kidneys. About 63% of a dose is excreted (10-40% unchanged) into the urine. Duration of effect is dose-related (30 minutes to 2 hours in humans).

過量

Because hypotension is the primary problem that would generally be seen, circulatory support should be instituted immediately. Only one human case of accidental massive overdose resulting in death has been reported (causal relationship not unequivocally established).

可用產品

劑型

  • Injection

人用標示

  • Inamrinone Lactate for Injection: 5 mg/mL (as lactate) in 20 mL ampules

各地核准狀態

暫無法規資料: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

儲存與穩定性

Store at room temperature and protect from light. Stable for 2 years after manufacture. Compatible with 0.45% or 0.9% sodium chloride injection. Incompatible with solutions containing dextrose or sodium bicarbonate.

飼主須知

  • ​僅限醫院使用：​ 此藥物需在具備重症監護條件的醫院內透過靜脈注射給藥。
  • ​試驗性質：​ 獸醫師應讓飼主了解，此藥物在犬貓的應用屬於「試驗性質」（仿單標示外使用）。
  • ​密集監測：​ 您的寵物在接受此藥物治療期間，需要持續監測心律（心電圖）與血壓。

VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。